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In their letter regarding my editorial, ‘When is one kidney
not enough?’,1 Stratta et al.2 argue that mutations of HNF-1b
should be considered as an etiology for unilateral renal
agenesis, and that genetic screening should be included in the
evaluation of such patients. Mice heterozygous for a
mutation leading to a deficiency in another transcription
factor, Six2, also exhibit severe renal maldevelopment, with
marked renal hypoplasia and reduced nephron number.3 In
addition to HNF-1b and Six2, there are a number of genes
contributing to renal morphogenesis, some with more subtle
phenotypic expression. These include variants of the RETand
PAX2 alleles, each of which may result in renal hypoplasia.4,5
Importantly, the combination of hypomorphic RET and
PAX2 alleles has an additive effect in reducing the kidney
volume (a proxy for nephron number) in human neonates.5
Continued elucidation of the molecular control of renal
morphogenesis will reveal more genes responsible for both
congenital renal anomalies and progression of renal
insufficiency. Once the temporal expression and relative
contribution of individual genes in the developing kidney are
better understood, the relative risk for progression can be
assigned. As pointed out by Stratta et al., such genetic
screening could be added to the development of biomarkers
of progression and monitoring risk factors already identified.
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Figure 1 | The large spectrum of macroscopic and microscopic renal diseases associated with hepatocyte nuclear factor 1b (HNF-1b)
mutations. As most of the identified HNF-1b target gene products colocalize in the primary celium, the crucial organelle that has an
important role in controlling the proliferation of tubular cells, it provides the background to explain the large spectrum of different
macroscopic and microscopic overt renal diseases, including single kidney, hypoplastic kidney, microcystic hypoplastic kidney, horse-shoe
kidney, multicystic kidney, glomerulomegalia, glomerulocystic kidney, or kidney with small tubular cysts, that have been described in
patients with alterations in the HNF-1b gene.
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Treatment of focal segmental
glomerulosclerosis
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To the Editor: In his excellent review, Meyrier1 outlined
the current ignorance about the pathogenesis of focal
segmental glomerulosclerosis (FSGS) and hoped for new
treatments aimed at counteracting the unknown factor(s)
responsible for FSGS rather than pursuing trials with agents
interfering with the immune system (or alternatively, acting
directly on the dysfunctional podocyte).
Although treatment of FSGS is still far from satisfactory,
the available data indicate that we are not ready to give up
these drugs, even though their use is driven by empiricism
rather than by a robust understanding of pathogenesis. A
treatment with oral glucocorticoids lasting 6 months or
more allows a remission (complete or partial) to be achieved
in about 60% of patients with FSGS and nephrotic
syndrome.2,3 The response to glucocorticoids is not confined
to patients with ‘tip’ lesions. In a series of patients studied,3
the response was not significantly different among the main
histological variants (classic scar 53%, collapsing lesion 64%,
‘tip’ lesion 78%). Patients who entered remission had a long-
term kidney survival significantly better than that observed
for untreated or non-responding patients.2,3 Calcineurin
inhibitors can also obtain a similar rate of response.4
Cytotoxic agents (for example, cyclophosphamide or chlor-
ambucil) have been almost abandoned, but a prolonged
administration, although potentially dangerous, may some-
times give a good rate of remission, when given as primary
therapy, and protect from relapses in steroid-responsive
patients.5
We concur with Meyrier on the pressing need for
characterizing the factors involved in FSGS and determining
their pathogenetic mechanisms. In the meantime, however,
we feel that so-called ‘immunosuppressive’ drugs still have a
role in the treatment of FSGS, whatever their mechanisms of
action.
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The comments of Ponticelli and Glassock1 on my minireview2
are pertinent. As long as the factors that induce the
podocytopathy of focal segmental glomerulosclerosis (FSGS)
are not identified and counteracted, its treatment will be
based on immunosuppressants. I gave my reasons to believe
that FSGS is not a T-cell-driven autoimmune disease, and that
steroids and calcineurin inhibitors reduce proteinuria through
their pharmacological rather than immunosuppressive prop-
erties. This should not be considered as a recommendation to
change our current therapeutic options. I am less optimistic
about the results of steroids in cellular forms of FSGS, such as
collapsing glomerulopathy (CG), the definition of which has
been the subject of dissension among pathologists, dissension
that may explain differing figures in terms of remission.
Albaqumi et al.,3 in their review of 125 cases of CG, found a
meager figure (28%) for remissions. Likewise, I share the
opinion of Braun et al.,4 based on a Cochrane database
analysis, that alkylating agents are of no avail in steroid-
resistant FSGS. Notwithstanding these disagreements, I fully
agree on the fact that treatment of FSGS is mandatory.
Considering that an association of steroids and a calcineurin
inhibitor is credited with the best remission rates, and that
both classes of drugs are immunosuppressants but also
antiproteinuric agents, is reassuring. These drugs should be
used until other options based on new laboratory findings
lead to the elucidation of the etiology of one of the most
elusive causes of idiopathic nephrotic syndrome.
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